Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/39621161/ below:

Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study

Observational Study

Affiliations

• ¹ Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
• ² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
• ³ Harvard Medical School, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
• ⁴ Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina.
• ⁵ Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
• ⁶ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
• ⁷ Harvard Medical School, Boston, MA, USA.
• ⁸ St. Elizabeth Medical Center, Boston, MA, USA.
• ⁹ Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.

• PMID: 39621161
• DOI: 10.1007/s10549-024-07562-w

Item in Clipboard

Observational Study

José Pablo Leone et al. Breast Cancer Res Treat. 2025 Apr.

• ¹ Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
• ² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
• ³ Harvard Medical School, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
• ⁴ Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina.
• ⁵ Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
• ⁶ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
• ⁷ Harvard Medical School, Boston, MA, USA.
• ⁸ St. Elizabeth Medical Center, Boston, MA, USA.
• ⁹ Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.

• PMID: 39621161
• DOI: 10.1007/s10549-024-07562-w

Item in Clipboard

Purpose: The COVID-19 pandemic created significant disruptions in the diagnosis and treatment of breast cancer (BC). Several public health measures were taken with limited evidence on their potential impact. In this observational study, we sought to compare the incidence of BC, treatment patterns, and mortality during 2020 versus 2018 and 2019.

Methods: Using the Surveillance, Epidemiology, and End Results program, we identified 37,834 patients with ductal carcinoma in situ (DCIS) and 199,594 with invasive BC between 2018 and 2020. We assessed age-adjusted incidence rates of DCIS and invasive BC as cases per 100,000, treatment patterns, and mortality in 2020 versus 2018 and 2019.

Results: From 2019 to 2020, the incidence of female DCIS decreased from 36.4 to 31.0, and the incidence of female invasive BC decreased from 184.2 to 166.6. Among females, the relative reductions in incidence from 2019 to 2020 were 14.8% for DCIS, 12.1% for stage I, 5.8% for stage II, 2.6% for stage III, and 1.9% for stage IV. Comparing 2020 to 2018-2019 in invasive BC, we observed significant changes in treatment patterns with decreased use of surgery or radiation and increased use of chemotherapy. The 12-month mortality rates were 4.49%, 4.37%, and 4.57% for 2018, 2019 and 2020, respectively. In the Cox model, there were no significant differences in mortality between patients diagnosed in 2020 versus 2018 or 2019.

Conclusions: During 2020, the incidence of BC decreased significantly. There were reductions in surgery and radiation use, but not in chemotherapy. Although vaccines were largely unavailable and COVID-19 treatments were in development, we saw no differences in 12-month mortality in 2020 versus prior years. The impact on BC-specific outcomes requires further follow-up.

Keywords: Breast cancer; COVID; Death; Health policy; Vaccines.

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PubMed Disclaimer

Declarations. Competing interests: JPL received research funding from Kazia Therapeutics and Lilly; and consulting honoraria from Minerva Biotechnologies. SMT reports consulting or advisory role for Novartis, Pfizer (SeaGen), Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gilead, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Johnson&Johnson/Ambrx, Launch Therapeutics, Zuellig Pharma, and Bicycle Therapeutics; institutional research support from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, OncoPep, Daiichi Sankyo, and Menarini/Stemline; and travel support from Eli Lilly, Sanofi, Gilead, Jazz Pharmaceuticals, Pfizer, and Arvinas. NUL reports consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., and Eisai; institutional research support from Genentech (and Zion Pharmaceutical as part of GNE), Pfizer, Merck, Seattle Genetics (now Pfizer), Olema Pharmaceuticals, and AstraZeneca; royalties from Up to date (book); and travel support from Olema Pharmaceuticals and AstraZeneca. Ethics approval: The study was exempted from Institutional Review Board review because we utilized de-identified, previously collected, publicly available data. The study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Consent to participate: Not applicable. Consent for publication: Not applicable.

• Visitor Restrictions During the COVID-19 Pandemic and Increased Falls With Harm at a Canadian Hospital: An Exploratory Study.

  Shennan S, Coyle N, Lockwood B, DiDiodato G. Shennan S, et al. J Patient Saf. 2024 Sep 1;20(6):434-439. doi: 10.1097/PTS.0000000000001237. Epub 2024 Jun 26. J Patient Saf. 2024. PMID: 38917342

• Exploring the relationship between working from home, mental and physical health and wellbeing: a systematic review.

  Blank L, Hock E, Cantrell A, Baxter S, Goyder E. Blank L, et al. Public Health Res (Southampt). 2023 May;11(4):1-100. doi: 10.3310/AHFF6175. Public Health Res (Southampt). 2023. PMID: 37452651

• Substance use during the COVID-19 pandemic: What is really happening?

  Mellos E, Paparrigopoulos T. Mellos E, et al. Psychiatriki. 2022 Mar 28;33(1):17-20. doi: 10.22365/jpsych.2022.072. Epub 2022 Feb 21. Psychiatriki. 2022. PMID: 35255473 English, Greek, Modern.

• Antibody tests for identification of current and past infection with SARS-CoV-2.

  Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H, Buckley BS, Probyn K, Sguassero Y, Davenport C, Cunningham J, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Struyf T, Van den Bruel A, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Deeks JJ; Cochrane COVID-19 Diagnostic Test Accuracy Group. Fox T, et al. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article. Review.

1. 1. Yin K, Singh P, Drohan B, Hughes KS (2020) Breast imaging, breast surgery, and cancer genetics in the age of COVID-19. Cancer 126(20):4466–4472. https://doi.org/10.1002/cncr.33113 - DOI - PubMed
2. 1. Patt D, Gordan L, Diaz M et al (2020) Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin Cancer Inform 4:1059–1071. https://doi.org/10.1200/CCI.20.00134 - DOI - PubMed
3. 1. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD (2021) Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncol 7(3):458–460. https://doi.org/10.1001/jamaoncol.2020.7600 - DOI - PubMed - PMC
4. 1. Chen RC, Haynes K, Du S, Barron J, Katz AJ (2021) Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA Oncol 7(6):878–884. https://doi.org/10.1001/jamaoncol.2021.0884 - DOI - PubMed - PMC
5. 1. Nyante SJ, Benefield TS, Kuzmiak CM, Earnhardt K, Pritchard M, Henderson LM (2021) Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures. Cancer 127(12):2111–2121. https://doi.org/10.1002/cncr.33460 - DOI - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3